602 related articles for article (PubMed ID: 23429702)
1. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.
Kim JH; Resende R; Wennekes T; Chen HM; Bance N; Buchini S; Watts AG; Pilling P; Streltsov VA; Petric M; Liggins R; Barrett S; McKimm-Breschkin JL; Niikura M; Withers SG
Science; 2013 Apr; 340(6128):71-5. PubMed ID: 23429702
[TBL] [Abstract][Full Text] [Related]
2. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
[TBL] [Abstract][Full Text] [Related]
4. Recent progress and challenges in the discovery of new neuraminidase inhibitors.
Chamni S; De-Eknamkul W
Expert Opin Ther Pat; 2013 Apr; 23(4):409-23. PubMed ID: 23369206
[TBL] [Abstract][Full Text] [Related]
5. Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors.
Vavricka CJ; Liu Y; Kiyota H; Sriwilaijaroen N; Qi J; Tanaka K; Wu Y; Li Q; Li Y; Yan J; Suzuki Y; Gao GF
Nat Commun; 2013; 4():1491. PubMed ID: 23422659
[TBL] [Abstract][Full Text] [Related]
6. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?
Cheng CK; Tsai CH; Shie JJ; Fang JM
Future Med Chem; 2014 May; 6(7):757-74. PubMed ID: 24941871
[TBL] [Abstract][Full Text] [Related]
7. Neuraminidase inhibitors as potential anti-influenza drugs.
Bamford MJ
J Enzyme Inhib; 1996; 10(1):1-16. PubMed ID: 8835926
[No Abstract] [Full Text] [Related]
8. Neuraminidase inhibitors as antiviral agents.
Alymova IV; Taylor G; Portner A
Curr Drug Targets Infect Disord; 2005 Dec; 5(4):401-9. PubMed ID: 16535861
[TBL] [Abstract][Full Text] [Related]
9. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
10. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
[TBL] [Abstract][Full Text] [Related]
11. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase.
Varghese JN; Epa VC; Colman PM
Protein Sci; 1995 Jun; 4(6):1081-7. PubMed ID: 7549872
[TBL] [Abstract][Full Text] [Related]
13. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Liu KC; Lee PS; Wang SY; Cheng YS; Fang JM; Wong CH
Bioorg Med Chem; 2011 Aug; 19(16):4796-802. PubMed ID: 21778065
[TBL] [Abstract][Full Text] [Related]
14. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
[TBL] [Abstract][Full Text] [Related]
15. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S
Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807
[No Abstract] [Full Text] [Related]
16. Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Smith BJ; McKimm-Breshkin JL; McDonald M; Fernley RT; Varghese JN; Colman PM
J Med Chem; 2002 May; 45(11):2207-12. PubMed ID: 12014958
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
Taylor NR; Cleasby A; Singh O; Skarzynski T; Wonacott AJ; Smith PW; Sollis SL; Howes PD; Cherry PC; Bethell R; Colman P; Varghese J
J Med Chem; 1998 Mar; 41(6):798-807. PubMed ID: 9526556
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
19. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
Wen WH; Wang SY; Tsai KC; Cheng YS; Yang AS; Fang JM; Wong CH
Bioorg Med Chem; 2010 Jun; 18(11):4074-84. PubMed ID: 20452227
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
Ye D; Shin WJ; Li N; Tang W; Feng E; Li J; He PL; Zuo JP; Kim H; Nam KY; Zhu W; Seong BL; No KT; Jiang H; Liu H
Eur J Med Chem; 2012 Aug; 54():764-70. PubMed ID: 22795831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
